ICN Pharmaceuticals Acquires Solco
- Share via
Costa Mesa drug maker ICN Pharmaceuticals Inc. said Wednesday it acquired Swiss pharmaceutical company Solco Basel AG. Financial terms weren’t disclosed.
ICN said privately held Solco, which sells dermatology, skin-care, wound-healing and ophthalmology products in Europe, the Middle East and Asia, had sales of $28 million in 1999. Last year, ICN earned $118.6 million, or $1.45 a diluted share, on revenue of $747.4 million.
ICN’s stock rose 13 cents a share to $28.56 on the New York Stock Exchange.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
